The forty-first meeting of the West Virginia Medicaid Drug Utilization Review Board was called to order with the following in attendance:

Members Present:
Karen Reed, R.Ph., Chairperson
Steve Judy, R.Ph.
Lester Labus, M.D.
Kerry Stitzinger, R.Ph.
Chris Terpening, PharmD., Ph.D.
Mary Nemeth-Pyles, M.S.N., R.N., C.S.
Pat Regan, PharmD.
Myra Chiang, M.D.
James Bennett, M.D.
George Bryant, PA-C
Ernest Miller, D.O.
John R. Vanin, M.D.
Dan Dickman, M.D.
David Elliott, PharmD.

Members Absent:
Bernie Smith, R.Ph., M.B.A., M.H.A.
Matthew Watkins, D.O.
Mitch Shaver, M.D.
Kevin Yingling, R.Ph., M.D.

Interested Parties Present:
Bristol Myers Squibb: Karen Brett Long, John Hymen, Bob Beatty
Genentech: Bob McConnell
Government Relations Specialist: Thom Stevens
Jansen: Olga Mitelman, Bert Wickey
Johnson & Johnson: Raymona Kinneberg
KOS Pharma: Kimberli Anderson, Joseph A. Dearth
Merck: Bob Kelley, Ed Davis
Novartis: Steve Mitchell, Michael Beatty
Pfizer: Missy Sutphin, Eddie Hines, Steve Swandell
PhRMA: Bryan Brown
Roche: Archie Shew
Schering: Rob Marsh
Sepracor: Sue Ellen Shrout, Tony Severoni
Takeda: Sandy Hagenbrock
TAP: Stacey Poole
WVDH: Angela Mackay, MD

I. INTRODUCTIONS

Karen Reed, Chairperson, welcomed everyone to the Board meeting. Members of the Board and interested parties introduced themselves.
II. APPROVAL OF THE MAY 21, 2003, MINUTES

A motion was made to accept the minutes of the May 21, 2003, DUR Board meeting as written. The motion was seconded and passed unanimously.

III. OLD BUSINESS

A. Quantity Limits for Strattera® (automoxetine)

Ms. Reed read the proposed criteria for Strattera. Quantity limit criteria was approved as presented. A motion was made and seconded, votes were taken and the motion carried.

B. Prior Authorization Criteria for Fuzeon®

Ms. Reed read the proposed criteria for Fuzeon. Prior authorization criteria was approved as presented. A motion was made and seconded, votes were taken and the motion carried.

IV. NEW BUSINESS

A. Report on Prospective Drug Utilization Review System (UniDUR) – KayLynn Wight, R.Ph., Unisys (new MMIS vendor) (See attachment)

Peggy King informed the audience that ACS is our current fiscal agent who processes our point-of-sale pharmacy claims. Unisys will be the new vendor beginning in February 2004. She introduced KayLynn Wight, pharmacist for Unisys. KayLynn gave a presentation on the Unisys prospective drug utilization review system, UniDUR.

Ms. King discussed using hard edits for the therapeutic duplications of narcotic analgesics when more than one prescriber is involved. Pharmacists will be required to intervene and then call for an authorization code when this occurs. Another committee member asked about double maximum dosages and if an alert would be given. An edit to look for this problem could be added to the system.

B. Review of Prior Authorization Criteria for Zetia®

Ms. Reed read the amended approved criteria for Zetia and Welchol. Vicki Cunningham explained that this criteria had been finalized and voted upon by e-mail with the Board members during the summer.

C. Review of Phase VI of the Preferred Drug List and Prior Authorization Criteria

Ms. Reed read the proposed criteria for Phase VI of the Preferred Drug List. Prior authorization criteria was approved as presented. A motion was made and seconded, votes were taken and the motion carried.

D. Prior Authorization Criteria for Xolair®

Ms. Reed read the proposed criteria for Xolair. A representative from Amgen gave a presentation about the indications and usages of Xolair. A short discussion ensued. Karen Reed stated that the criteria would be reviewed and voted upon at the next meeting.
E. Insulin Sooner – Disease Management Proposal from NovoNordisk

Presentation will be given at the next meeting.

V. REPORTS

Dr. Joseph stated that there had been several requests for azithromycin on a long term basis for treatment of children with cystic fibrosis. These were for 500 mg. three times a week to improve lung function and quality of life. The three studies that have been done have documented that patients having this treatment show a reduction in acute antibiotic therapy treatments and hospitalization. The patients in the study met certain criteria. Dr. Joseph was concerned that the trials have been done only for six months at a time and no data is available to show outcomes when therapy is discontinued. Committee members decided they would like to see the data from studies on azithromycin treatment for cystic fibrosis at the next meeting.

A. Heritage Information Systems (See Attachment)

Due to time constraints, Robert Berringer, Heritage Information Systems, asked that the Board refer to the written report that had been distributed.

B. Rational Drug Therapy Program (See Attachment)

A written report was distributed and an oral report was given by Steve Small, Rational Drug Therapy Program Director.

C. ACS Second Quarter Report (See Attachment)

There were no comments from the Board regarding the ACS Quarterly Report.

VI. OTHER BUSINESS

No other business was discussed.

VII. OPEN TO THE FLOOR

No remarks from the floor.

VIII. NEXT MEETING AND ADJOURNMENT

A motion was made and seconded that the meeting be adjourned. All were in favor. The meeting was concluded at 5:45 p.m. The next meeting will be held on Wednesday, November 19, 2003.

Respectfully submitted,

Lynda L. Edwards
Secretary